Hikal Experiences Shift in Evaluation Amidst Strong Profit Growth and Market Positioning

Hikal, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the technical outlook, indicating a transition from a mildly bearish to a bearish stance.
Key financial metrics reveal that Hikal's net sales have experienced an annual growth rate of 4.38% over the past five years, while operating profit growth has been notably lower at 0.34%. Despite these figures, the company reported a significant increase in net profit of 191.86% for the quarter ending March 2025, with a profit before tax (PBT) of Rs 67.80 crore, marking a growth of 177.3% compared to the previous four-quarter average. The return on capital employed (ROCE) stands at 9.7%, with a peak of 9.82% in the half-yearly assessment, suggesting an attractive valuation relative to its enterprise value to capital employed ratio of 2.4.

Over the past year, Hikal's stock has generated a return of 0.88%, while profits have increased by 30.7%. The stock is currently trading at a discount compared to its peers' average historical valuations, reflecting its position in the market.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.